<?xml version="1.0" encoding="UTF-8"?>
<drugbank xmlns="http://www.drugbank.ca" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.drugbank.ca http://www.drugbank.ca/docs/drugbank.xsd" version="4.3">
    <drug type="biotech" created="2005-06-13" updated="2015-11-10">
        <drugbank-id primary="true">DB00002</drugbank-id>
        <drugbank-id>BIOD00071</drugbank-id>
        <drugbank-id>BTD00071</drugbank-id>
        <name>Cetuximab</name>
        <description>Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.</description>
        <cas-number>205923-56-4</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references/>
        <synthesis-reference/>
        <indication>For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.</indication>
        <pharmacodynamics>Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor–alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.</pharmacodynamics>
        <mechanism-of-action>Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.</mechanism-of-action>
        <toxicity>Single doses of cetuximab higher than 500 mg/m&lt;sup&gt;2&lt;/sup&gt; have not been tested. There is no experience with overdosage in human clinical trials.&#13;
&#13;
        </toxicity>
        <metabolism/>
        <absorption/>
        <half-life>114 hrs</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance/>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Anti EGFR</synonym>
            <synonym language="" coder="">IMC-C225</synonym>
        </synonyms>
        <products>
            <product>
                <name>Erbitux</name>
                <ndc-id>66733-948_8518fcc5-91cf-46e6-8fd2-b7d8418200a1</ndc-id>
                <ndc-product-code>66733-948</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2004-02-12</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2 mg/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA125084</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Erbitux</name>
                <ndc-id>66733-958_8518fcc5-91cf-46e6-8fd2-b7d8418200a1</ndc-id>
                <ndc-product-code>66733-958</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2007-10-02</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2 mg/mL</strength>
                <route>intravenous</route>
                <fda-application-number>BLA125084</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Erbitux</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02271249</dpd-id>
                <started-marketing-on>2008-10-28</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>2 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
        </products>
        <international-brands/>
        <mixtures>
            <mixture>
                <name>Erbitux</name>
                <ingredients>Cetuximab</ingredients>
            </mixture>
            <mixture>
                <name>Erbitux</name>
                <ingredients>Cetuximab</ingredients>
            </mixture>
            <mixture>
                <name>Erbitux</name>
                <ingredients>Cetuximab</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Cardinal Health</name>
                <url>http://www.cardinal.com</url>
            </packager>
            <packager>
                <name>Catalent Pharma Solutions</name>
                <url>http://www.catalent.com</url>
            </packager>
            <packager>
                <name>ImClone Systems Inc.</name>
                <url>http://www.imclone.com</url>
            </packager>
            <packager>
                <name>Oso Biopharmaceuticals Manufacturing LLC</name>
                <url/>
            </packager>
        </packagers>
        <manufacturers/>
        <prices/>
        <categories>
            <category>
                <category>Antineoplastic Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>2 mg</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>intravenous</route>
                <strength>2 mg/mL</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L01XC06">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L01">ANTINEOPLASTIC AGENTS</level>
                <level code="L01X">OTHER ANTINEOPLASTIC AGENTS</level>
                <level code="L01XC">Monoclonal antibodies</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes/>
        <patents>
            <patent>
                <number>1340417</number>
                <country>Canada</country>
                <approved>1999-03-02</approved>
                <expires>2016-03-02</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions/>
        <sequences>
            <sequence format="FASTA">&gt;Cetuximab heavy chain
                QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYN
                TPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAA
                STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
                LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSPKSCDKTHTCPPCPAPELL
                GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
                YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR
                DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS
                RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</sequence>
            <sequence format="FASTA">&gt;Cetuximab light chain
                DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPS
                RFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPP
                SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
                LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Melting Point</kind>
                <value>61 °C (FAB fragment), 71 °C (whole mAb)</value>
                <source>Vermeer, A.W.P. &amp; Norde, W., Biophys. J. 78:394-404 (2000)</source>
            </property>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.413</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.48</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>145781.6000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C6484H10042N1732O2023S36</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13175</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>66733-948-23</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00228</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10040</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Cetuximab</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/erbitux.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/cetuximab.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00474</smpdb-id>
                <name>Cetuximab Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00002</drugbank-id>
                        <name>Cetuximab</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00533</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects>
            <effect>
                <protein-name>Low affinity immunoglobulin gamma Fc region receptor II-a</protein-name>
                <gene-symbol>FCGR2A</gene-symbol>
                <uniprot-id>P12318</uniprot-id>
                <rs-id>rs1801274</rs-id>
                <allele/>
                <defining-change>H allelle</defining-change>
                <description>Increased progression free survival</description>
                <pubmed-id>17704420</pubmed-id>
            </effect>
            <effect>
                <protein-name>Low affinity immunoglobulin gamma Fc region receptor III-A</protein-name>
                <gene-symbol>FCGR3A</gene-symbol>
                <uniprot-id>P08637</uniprot-id>
                <rs-id>rs396991</rs-id>
                <allele/>
                <defining-change>A &gt; C</defining-change>
                <description>Better response to drug therapy (longer progression free survival) with the F allele</description>
                <pubmed-id>17704420</pubmed-id>
            </effect>
        </snp-effects>
        <snp-adverse-drug-reactions/>
        <targets>
            <target position="1">
                <id>BE0000767</id>
                <name>Epidermal growth factor receptor</name>
                <organism>Human</organism>
                <actions>
                    <action>antagonist</action>
                </actions>
                <references># Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10480573&#13;
                    # Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10601294&#13;
                    # Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10628369&#13;
                    # Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11408594&#13;
                    # Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11431346&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00533" source="Swiss-Prot">
                    <name>Epidermal growth factor receptor</name>
                    <general-function>Involved in transmembrane receptor protein tyrosine kinase activity</general-function>
                    <specific-function>Isoform 2/truncated isoform may act as an antagonist</specific-function>
                    <gene-name>EGFR</gene-name>
                    <locus>7p12</locus>
                    <cellular-location>Cell membrane; single-pass type I membrane protein. Isoform 2:Secreted protein</cellular-location>
                    <transmembrane-regions>646-668</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.67</theoretical-pi>
                    <molecular-weight>134279.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3236</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>EGFR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>EGFR</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X00588</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>757924</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00533</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>EGFR_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 2.7.10.1</synonym>
                        <synonym>Epidermal growth factor receptor precursor</synonym>
                        <synonym>Receptor tyrosine-protein kinase ErbB-1</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Epidermal growth factor receptor precursor
                        MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
                        VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
                        VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
                        QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
                        TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
                        VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
                        NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
                        ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
                        FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
                        LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
                        GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
                        ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
                        GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
                        CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
                        RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
                        GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
                        FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
                        QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
                        SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
                        TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
                        APQSSEFIGA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;3633 bp
                        ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG
                        GCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG
                        TTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG
                        GTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG
                        ACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT
                        TTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA
                        GTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA
                        CAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG
                        AGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC
                        CAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG
                        GGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC
                        GGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC
                        ACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC
                        AAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC
                        CCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG
                        GTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA
                        GACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA
                        GGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA
                        AACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC
                        TTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA
                        ATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT
                        GAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC
                        GTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT
                        GTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG
                        TTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG
                        GCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC
                        AGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAG
                        CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA
                        GAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
                        CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG
                        GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC
                        CATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG
                        CCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG
                        GCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG
                        AGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC
                        CAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC
                        GGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT
                        CCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC
                        GATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC
                        TGCCTCACCTCCACCGTGCAACTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC
                        TATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG
                        ATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC
                        AGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA
                        CTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG
                        ATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC
                        GGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC
                        AGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC
                        ATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG
                        TTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC
                        ATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC
                        CTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG
                        CAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA
                        ACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC
                        AAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC
                        AGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG
                        CCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC
                        AGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC
                        ACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA
                        GGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA
                        GCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC
                        GCGCCACAAAGCAGTGAATTTATTGGAGCATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF07714</identifier>
                            <name>Pkinase_Tyr</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00757</identifier>
                            <name>Furin-like</name>
                        </pfam>
                        <pfam>
                            <identifier>PF01030</identifier>
                            <name>Recep_L_domain</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transmembrane receptor protein tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>epidermal growth factor receptor activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein-tyrosine kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ATP binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>purine nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity, transferring phosphorus-containing groups</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>adenyl nucleotide binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>transferase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>protein kinase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein amino acid phosphorylation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>enzyme linked receptor protein signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell communication</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transmembrane receptor protein tyrosine kinase signaling pathway</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>biopolymer modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cell surface receptor linked signal transduction</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein modification</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="2">
                <id>BE0000901</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                <organism>Human</organism>
                <actions/>
                <references># Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16336752</references>
                <known-action>unknown</known-action>
                <polypeptide id="O75015" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils</specific-function>
                    <gene-name>FCGR3B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.71</theoretical-pi>
                    <molecular-weight>26216.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3620</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16863</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31322</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O75015</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16b antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-beta</synonym>
                        <synonym>Fc-gamma RIIIb</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIb</synonym>
                        <synonym>IgG Fc receptor III-1</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-B precursor
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
                        VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
                        AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="3">
                <id>BE0002093</id>
                <name>Complement C1r subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00736" source="Swiss-Prot">
                    <name>Complement C1r subcomponent</name>
                    <general-function/>
                    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system</specific-function>
                    <gene-name>C1R</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.24</theoretical-pi>
                    <molecular-weight>80174.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1246</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04701</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29539</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00736</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1r subcomponent precursor</synonym>
                        <synonym>Complement component 1, r subcomponent</synonym>
                        <synonym>EC 3.4.21.41</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1r subcomponent
                        MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
                        QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
                        SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
                        ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
                        DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
                        RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
                        DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
                        ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
                        TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
                        SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
                        EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
                        RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2118 bp
                        ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
                        ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
                        AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
                        CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
                        GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
                        GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
                        TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
                        GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
                        TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
                        GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
                        GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
                        AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
                        GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
                        GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
                        AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
                        CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
                        ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
                        GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
                        GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
                        AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
                        CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
                        GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
                        GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
                        AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
                        ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
                        GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
                        CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
                        AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
                        CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
                        AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
                        GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
                        GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
                        GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
                        AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
                        AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
                        ATGGAGGAGGAGGACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="4">
                <id>BE0002094</id>
                <name>Complement C1q subcomponent subunit A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02745" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit A</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QA</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.45</theoretical-pi>
                    <molecular-weight>26017.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1241</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF135157</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4894854</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02745</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit A
                        MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
                        TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
                        RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
                        GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
                        IFPSA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
                        GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
                        AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
                        ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
                        AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA
                        GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
                        CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
                        GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
                        TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
                        GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
                        GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
                        CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
                        ATCTTCCCATCTGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="5">
                <id>BE0002095</id>
                <name>Complement C1q subcomponent subunit B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02746" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit B</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QB</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.87</theoretical-pi>
                    <molecular-weight>26460.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1242</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X03084</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>573114</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit B
                        MKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK
                        GLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI
                        AFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV
                        NLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF
                        SGFLLFPDMEA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;688 bp
                        CCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG
                        GACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC
                        AGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA
                        TCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG
                        AGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC
                        TGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT
                        GATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC
                        CGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT
                        GCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT
                        CCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA
                        GGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT
                        CCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="6">
                <id>BE0002096</id>
                <name>Complement C1q subcomponent subunit C</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02747" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit C</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QC</gene-name>
                    <locus>1p36.11</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>25774.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF087892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33150626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit C precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit C
                        MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
                        GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
                        VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
                        LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
                        LLFPD</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
                        CTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
                        CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
                        GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
                        CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
                        CCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
                        GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
                        AACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC
                        AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
                        CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
                        CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
                        GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
                        CTGCTCTTCCCCGACTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="7">
                <id>BE0002097</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17704420</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08637" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis</specific-function>
                    <gene-name>FCGR3A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>209-229</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.21</theoretical-pi>
                    <molecular-weight>29089.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3619</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16a antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-alpha</synonym>
                        <synonym>Fc-gamma RIIIa</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIa</synonym>
                        <synonym>IgG Fc receptor III-2</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-A
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
                        VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
                        KDHKFKWRKDPQDK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;765 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA
                        AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG
                        AAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="8">
                <id>BE0001529</id>
                <name>Complement C1s subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P09871" source="Swiss-Prot">
                    <name>Complement C1s subcomponent</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4</specific-function>
                    <gene-name>C1S</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.59</theoretical-pi>
                    <molecular-weight>76685.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>763110</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P09871</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1S_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>C1 esterase</synonym>
                        <synonym>Complement C1s subcomponent precursor</synonym>
                        <synonym>EC 3.4.21.42</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1s subcomponent precursor
                        MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
                        LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
                        TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
                        TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
                        VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
                        NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
                        IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
                        CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
                        REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
                        MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
                        EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
                        TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2067 bp
                        ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
                        GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
                        GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
                        CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
                        AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
                        GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
                        ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
                        GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
                        GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
                        ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
                        AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
                        GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
                        GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
                        ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
                        AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
                        AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
                        TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
                        TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
                        ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
                        GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
                        TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
                        TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
                        GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
                        GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
                        AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
                        AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
                        GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
                        ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
                        GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
                        CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
                        GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
                        GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
                        CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
                        ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
                        GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="9">
                <id>BE0000710</id>
                <name>High affinity immunoglobulin gamma Fc receptor I</name>
                <organism>Human</organism>
                <actions/>
                <references># Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7547242</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12314" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor I</name>
                    <general-function>Involved in receptor signaling protein activity</general-function>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. High affinity receptor</specific-function>
                    <gene-name>FCGR1A</gene-name>
                    <locus>1q21.2-q21.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>293-313</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.08</theoretical-pi>
                    <molecular-weight>42632.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3613</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14356</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31332</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12314</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD64 antigen</synonym>
                        <synonym>Fc-gamma RI</synonym>
                        <synonym>FcRI</synonym>
                        <synonym>High affinity immunoglobulin gamma Fc receptor I precursor</synonym>
                        <synonym>IgG Fc receptor I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor I precursor
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
                        TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
                        IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
                        LQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1125 bp
                        ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
                        AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
                        TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
                        ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
                        GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
                        CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
                        GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
                        GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
                        AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
                        ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
                        CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
                        CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
                        ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
                        GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
                        CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
                        ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
                        AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
                        CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
                        CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="10">
                <id>BE0002098</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#13;
                    # Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17704420</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12318" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens</specific-function>
                    <gene-name>FCGR2A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.78</theoretical-pi>
                    <molecular-weight>34990.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3616</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31932</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182474</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-a</synonym>
                        <synonym>Fc-gamma-RIIa</synonym>
                        <synonym>FcRII-a</synonym>
                        <synonym>IgG Fc receptor II-a</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-a precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-a
                        MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
                        TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
                        SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS
                        HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
                        CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
                        KNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;954 bp
                        ATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
                        CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
                        GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
                        ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
                        CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
                        GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
                        TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
                        CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
                        AAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
                        CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
                        GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
                        GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
                        TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
                        CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
                        TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
                        AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="11">
                <id>BE0002099</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31994" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis</specific-function>
                    <gene-name>FCGR2B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.12</theoretical-pi>
                    <molecular-weight>34044.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3618</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U87560</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4099445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31994</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-b</synonym>
                        <synonym>Fc-gamma-RIIb</synonym>
                        <synonym>FcRII-b</synonym>
                        <synonym>IgG Fc receptor II-b</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-b precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-b
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
                        LEEPDDQNRI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;930 bp
                        ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG
                        TGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG
                        GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
                        CTGGAAGAGCCTGATGACCAGAACCGTATT</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target position="12">
                <id>BE0002100</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31995" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells</specific-function>
                    <gene-name>FCGR2C</gene-name>
                    <locus>1q23.3</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>224-246</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.9</theoretical-pi>
                    <molecular-weight>35578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32074</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31995</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2C_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-c</synonym>
                        <synonym>Fc-gamma-RIIc</synonym>
                        <synonym>FcRII-c</synonym>
                        <synonym>IgG Fc receptor II-c</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-c precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-c
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
                        APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;972 bp
                        ATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
                        AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
                        GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
                        GCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC
                        AGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
    <drug type="biotech" created="2005-06-13" updated="2013-09-13">
        <drugbank-id primary="true">DB00006</drugbank-id>
        <drugbank-id>BIOD00076</drugbank-id>
        <drugbank-id>BTD00076</drugbank-id>
        <name>Bivalirudin</name>
        <description>Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. </description>
        <cas-number>128270-60-0</cas-number>
        <groups>
            <group>approved</group>
            <group>investigational</group>
        </groups>
        <general-references># Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16466327&#13;
            # Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17381384&#13;
            # Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16553503&#13;
            # Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11156732&#13;
            # Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21108549&#13;
            # Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16614733&#13;
            # Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12851152</general-references>
        <synthesis-reference>Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, "Process for production of Bivalirudin." U.S. Patent US20070093423, issued April 26, 2007.</synthesis-reference>
        <indication>For treatment of heparin-induced thrombocytopenia and for the&#13;
            prevention of thrombosis. Bivalirudin is indicated for use in&#13;
            patients undergoing percutaneous coronary intervention (PCI), in&#13;
            patients at moderate to high risk acute coronary syndromes due to&#13;
            unstable angina or non-ST segment elevation in whom a PCI is planned.</indication>
        <pharmacodynamics>Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin. </pharmacodynamics>
        <mechanism-of-action>Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</mechanism-of-action>
        <toxicity>Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.</toxicity>
        <metabolism>80% proteolytic cleavage</metabolism>
        <absorption>Following intravenous administration, bivalirudin exhibits linear&#13;
            pharmacokinetics .  The mean steady state concentration is 12.3 +/-&#13;
            1.7mcg/mL after administration of an intravenous bolus of 1mg/kg&#13;
            followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.</absorption>
        <half-life>* Normal renal function: 25 min (in normal conditions)&#13;
            * Creatinine clearance 10-29mL/min: 57min&#13;
            * Dialysis-dependant patients: 3.5h</half-life>
        <protein-binding>Other than thrombin and red blood cells, bivalirudin does not bind to&#13;
            plasma proteins.</protein-binding>
        <route-of-elimination>Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.</route-of-elimination>
        <volume-of-distribution>0.2L/kg</volume-of-distribution>
        <clearance>* 3.4 mL/min/kg [Normal renal function]&#13;
            * 3.4 mL/min/kg [mild renal function]&#13;
            * 2.7 mL/min/kg [moderate renal function]&#13;
            * 2.8 mL/min/kg [severe renal function]&#13;
            * 1 mL/min/kg [Dialysis-dependent patients]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms/>
        <products>
            <product>
                <name>Angiomax</name>
                <ndc-id>55154-2275_799d3b00-809b-4abc-989c-05faccec49f8</ndc-id>
                <ndc-product-code>55154-2275</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020873</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Angiomax</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02246533</dpd-id>
                <started-marketing-on>2003-05-08</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>powder for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Angiomax</name>
                <ndc-id>65293-001_3ff32af9-cb93-41e5-99ef-a7c162b35d92</ndc-id>
                <ndc-product-code>65293-001</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2000-12-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020873</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Bivalirudin</name>
                <ndc-id>0409-8300_4530ae1c-394e-44f4-89c0-bacb0e6991a0</ndc-id>
                <ndc-product-code>0409-8300</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-07-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>ANDA090811</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Bivalirudin</name>
                <ndc-id>0409-8300_fa3b34fe-d666-42e6-a1d4-3dbcfab7a384</ndc-id>
                <ndc-product-code>0409-8300</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-07-14</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>ANDA090816</fda-application-number>
                <generic>true</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
            <product>
                <name>Bivalirudin</name>
                <ndc-id>0781-3158_def5f702-a45c-4a38-a49b-a017bb7f5f3c</ndc-id>
                <ndc-product-code>0781-3158</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2015-06-15</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
                <strength>250 mg</strength>
                <route>intravenous</route>
                <fda-application-number>NDA020873</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Angiox</name>
                <company/>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Bivalirudin</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Bivalirudin</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Bivalirudin</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Angiomax</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Angiomax</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
            <mixture>
                <name>Angiomax</name>
                <ingredients>Bivalirudin</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Ben Venue Laboratories Inc.</name>
                <url>http://www.benvenue.com</url>
            </packager>
            <packager>
                <name>Oryx Pharmaceuticals Inc.</name>
                <url/>
            </packager>
            <packager>
                <name>Sepracor Pharmaceuticals Inc.</name>
                <url>http://www.sepracor.com</url>
            </packager>
            <packager>
                <name>The Medicines Co.</name>
                <url>http://www.themedicinescompany.com</url>
            </packager>
        </packagers>
        <manufacturers>
            <manufacturer generic="false">The medicines co</manufacturer>
        </manufacturers>
        <prices>
            <price>
                <description>Angiomax 250 mg vial</description>
                <cost currency="USD">780.0</cost>
                <unit>vial</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antithrombins</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Powder for solution</form>
                <route>intravenous</route>
                <strength>250 mg</strength>
            </dosage>
            <dosage>
                <form>Injection, powder, lyophilized, for solution</form>
                <route>intravenous</route>
                <strength>250 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="B01AE06">
                <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
                <level code="B01">ANTITHROMBOTIC AGENTS</level>
                <level code="B01A">ANTITHROMBOTIC AGENTS</level>
                <level code="B01AE">Direct thrombin inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>20:12.04.12</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2065150</number>
                <country>Canada</country>
                <approved>1999-12-14</approved>
                <expires>2010-08-17</expires>
            </patent>
            <patent>
                <number>5196404</number>
                <country>United States</country>
                <approved>1993-05-23</approved>
                <expires>2010-05-23</expires>
            </patent>
            <patent>
                <number>7582727</number>
                <country>United States</country>
                <approved>2009-01-27</approved>
                <expires>2029-01-27</expires>
            </patent>
        </patents>
        <food-interactions>
            <food-interaction>Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark</food-interaction>
            <food-interaction>Echinacea</food-interaction>
        </food-interactions>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB00054</drugbank-id>
                <name>Abciximab</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01418</drugbank-id>
                <name>Acenocoumarol</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00945</drugbank-id>
                <name>Acetylsalicylic acid</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00009</drugbank-id>
                <name>Alteplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00029</drugbank-id>
                <name>Anistreplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06605</drugbank-id>
                <name>Apixaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB04272</drugbank-id>
                <name>Citric Acid</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06695</drugbank-id>
                <name>Dabigatran etexilate</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06779</drugbank-id>
                <name>Dalteparin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01254</drugbank-id>
                <name>Dasatinib</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01609</drugbank-id>
                <name>Deferasirox</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB03619</drugbank-id>
                <name>Deoxycholic Acid</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00304</drugbank-id>
                <name>Desogestrel</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00266</drugbank-id>
                <name>Dicoumarol</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00378</drugbank-id>
                <name>Dydrogesterone</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00974</drugbank-id>
                <name>Edetic Acid</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09075</drugbank-id>
                <name>Edoxaban</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01225</drugbank-id>
                <name>Enoxaparin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08794</drugbank-id>
                <name>Ethyl biscoumacetate</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00569</drugbank-id>
                <name>Fondaparinux sodium</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06730</drugbank-id>
                <name>Gestodene</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01109</drugbank-id>
                <name>Heparin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00078</drugbank-id>
                <name>Ibritumomab</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09053</drugbank-id>
                <name>Ibrutinib</name>
                <description>May enhance the adverse/toxic effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09079</drugbank-id>
                <name>Nintedanib</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08935</drugbank-id>
                <name>Obinutuzumab</name>
                <description>Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00686</drugbank-id>
                <name>Pentosan Polysulfate</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00498</drugbank-id>
                <name>Phenindione</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00946</drugbank-id>
                <name>Phenprocoumon</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00396</drugbank-id>
                <name>Progesterone</name>
                <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00015</drugbank-id>
                <name>Reteplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01207</drugbank-id>
                <name>Ridogrel</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06228</drugbank-id>
                <name>Rivaroxaban</name>
                <description>Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01398</drugbank-id>
                <name>Salicylate-sodium</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00086</drugbank-id>
                <name>Streptokinase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06206</drugbank-id>
                <name>Sugammadex</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06271</drugbank-id>
                <name>Sulodexide</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00031</drugbank-id>
                <name>Tenecteplase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09070</drugbank-id>
                <name>Tibolone</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00932</drugbank-id>
                <name>Tipranavir</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00374</drugbank-id>
                <name>Treprostinil</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00013</drugbank-id>
                <name>Urokinase</name>
                <description>May enhance the anticoagulant effect of Anticoagulants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00163</drugbank-id>
                <name>Vitamin E</name>
                <description>May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09030</drugbank-id>
                <name>Vorapaxar</name>
                <description>May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt;Bivalirudin sequence
                FPRPGGGGNGDFEEIPEEYL</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.985</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>3.91</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>2180.2853</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C98H138N24O33</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>12945</identifier>
            </external-identifier>
            <external-identifier>
                <resource>KEGG Drug</resource>
                <identifier>D03136</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>65293-001-01</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10032</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Bivalirudin</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic/angiomax.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/bivalirudin.html</url>
            </external-link>
        </external-links>
        <pathways>
            <pathway>
                <smpdb-id>SMP00277</smpdb-id>
                <name>Bivalirudin Action Pathway</name>
                <drugs>
                    <drug>
                        <drugbank-id>DB00006</drugbank-id>
                        <name>Bivalirudin</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01022</drugbank-id>
                        <name>Phylloquinone</name>
                    </drug>
                    <drug>
                        <drugbank-id>DB01373</drugbank-id>
                        <name>Calcium</name>
                    </drug>
                </drugs>
                <enzymes>
                    <uniprot-id>P00734</uniprot-id>
                    <uniprot-id>P00748</uniprot-id>
                    <uniprot-id>P02452</uniprot-id>
                    <uniprot-id>P03952</uniprot-id>
                    <uniprot-id>P03951</uniprot-id>
                    <uniprot-id>P00740</uniprot-id>
                    <uniprot-id>P00451</uniprot-id>
                    <uniprot-id>P12259</uniprot-id>
                    <uniprot-id>P00742</uniprot-id>
                    <uniprot-id>P02671</uniprot-id>
                    <uniprot-id>P02675</uniprot-id>
                    <uniprot-id>P02679</uniprot-id>
                    <uniprot-id>P00488</uniprot-id>
                    <uniprot-id>P05160</uniprot-id>
                    <uniprot-id>P00747</uniprot-id>
                    <uniprot-id>P00750</uniprot-id>
                    <uniprot-id>P08709</uniprot-id>
                    <uniprot-id>P13726</uniprot-id>
                    <uniprot-id>Q9BQB6</uniprot-id>
                    <uniprot-id>P38435</uniprot-id>
                </enzymes>
            </pathway>
        </pathways>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000048</id>
                <name>Prothrombin</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060732&#13;
                    # Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11504570&#13;
                    # Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11833835&#13;
                    # Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11923794&#13;
                    # Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11929334&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P00734" source="Swiss-Prot">
                    <name>Prothrombin</name>
                    <general-function>Involved in blood clotting cascade</general-function>
                    <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C</specific-function>
                    <gene-name>F2</gene-name>
                    <locus>11p11-q12</locus>
                    <cellular-location>Secreted protein; extracellular space</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>5.7</theoretical-pi>
                    <molecular-weight>70037.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3535</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>F2</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M17262</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339641</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00734</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>THRB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Activated Factor II [IIa]</synonym>
                        <synonym>Coagulation factor II</synonym>
                        <synonym>EC 3.4.21.5</synonym>
                        <synonym>Prothrombin precursor</synonym>
                        <synonym>Thrombin</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Prothrombin precursor
                        MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
                        VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
                        NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
                        CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
                        QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
                        DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
                        DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
                        DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
                        VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
                        RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
                        GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1869 bp
                        ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
                        CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
                        GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC
                        GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
                        GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
                        GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
                        AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
                        GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
                        GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
                        TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
                        GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
                        TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
                        CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
                        TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
                        GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
                        GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
                        CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
                        CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
                        GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
                        CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
                        GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
                        GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG
                        ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
                        CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
                        GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
                        GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
                        AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
                        CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
                        GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
                        CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
                        GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
                        GGAGAGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00594</identifier>
                            <name>Gla</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00051</identifier>
                            <name>Kringle</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>thrombin activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>hemostasis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>blood coagulation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>organismal physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>regulation of body fluids</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes>
            <enzyme position="1">
                <id>BE0001075</id>
                <name>Myeloperoxidase</name>
                <organism>Human</organism>
                <actions>
                    <action>inhibitor</action>
                </actions>
                <references># Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. Epub 2008 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18701766[</references>
                <known-action>unknown</known-action>
                <polypeptide id="P05164" source="Swiss-Prot">
                    <name>Myeloperoxidase</name>
                    <general-function>Involved in peroxidase activity</general-function>
                    <specific-function>Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity</specific-function>
                    <gene-name>MPO</gene-name>
                    <locus>17q23.1</locus>
                    <cellular-location>Lysosome</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.14</theoretical-pi>
                    <molecular-weight>83870.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:7218</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>MPO</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>MPO</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>J02694</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>189040</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P05164</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>PERM_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>EC 1.11.1.7</synonym>
                        <synonym>MPO</synonym>
                        <synonym>Myeloperoxidase precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Myeloperoxidase precursor
                        MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
                        LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
                        VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
                        NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
                        QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
                        PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
                        GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
                        REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
                        SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
                        GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
                        AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
                        LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
                        NSYPRDFVNCSTLPALNLASWREAS</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2238 bp
                        ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT
                        GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG
                        GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG
                        TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG
                        CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC
                        TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC
                        GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC
                        ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC
                        CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC
                        AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG
                        GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC
                        GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT
                        CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC
                        CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC
                        TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC
                        CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC
                        GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC
                        ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG
                        GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC
                        AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG
                        GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT
                        CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG
                        AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG
                        GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT
                        TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC
                        GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA
                        CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA
                        GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG
                        AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG
                        CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT
                        GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG
                        CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC
                        GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC
                        CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG
                        GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC
                        CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC
                        AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC
                        TGGAGGGAAGCCTCCTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF03098</identifier>
                            <name>An_peroxidase</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>function</category>
                            <description>antioxidant activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peroxidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>oxygen and reactive oxygen species metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to oxidative stress</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
                <inhibition-strength>unknown</inhibition-strength>
                <induction-strength>unknown</induction-strength>
            </enzyme>
        </enzymes>
        <carriers/>
        <transporters/>
    </drug>	
    <drug type="biotech" created="2005-06-13" updated="2015-04-20">
        <drugbank-id primary="true">DB00051</drugbank-id>
        <drugbank-id>BIOD00049</drugbank-id>
        <drugbank-id>BTD00049</drugbank-id>
        <name>Adalimumab</name>
        <description>Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.</description>
        <cas-number>331731-18-1</cas-number>
        <groups>
            <group>approved</group>
        </groups>
        <general-references># PDB sequence "Link":http://www.rcsb.org/pdb/download/downloadFile.do?fileFormat=FASTA&amp;compression=NO&amp;structureId=1IGT&#13;
            # Patent Information "Link":http://www.freepatentsonline.com/6090382.html</general-references>
        <synthesis-reference/>
        <indication>For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.</indication>
        <pharmacodynamics>Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.</pharmacodynamics>
        <mechanism-of-action>Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.</mechanism-of-action>
        <toxicity/>
        <metabolism>Most likely removed by opsonization via the reticuloendothelial system.</metabolism>
        <absorption/>
        <half-life>10-20 days.</half-life>
        <protein-binding/>
        <route-of-elimination/>
        <volume-of-distribution/>
        <clearance>* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]</clearance>
        <classification>
            <description/>
            <direct-parent>Peptides</direct-parent>
            <kingdom>Organic Compounds</kingdom>
            <superclass>Organic Acids</superclass>
            <class>Carboxylic Acids and Derivatives</class>
            <subclass>Amino Acids, Peptides, and Analogues</subclass>
        </classification>
        <salts/>
        <synonyms>
            <synonym language="" coder="">Ig gamma-1 chain C region</synonym>
        </synonyms>
        <products>
            <product>
                <name>Humira</name>
                <ndc-id/>
                <ndc-product-code/>
                <dpd-id>02258595</dpd-id>
                <started-marketing-on>2004-09-24</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>solution</dosage-form>
                <strength>40 mg</strength>
                <route>subcutaneous</route>
                <fda-application-number/>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>Canada</country>
                <source>DPD</source>
            </product>
            <product>
                <name>Humira</name>
                <ndc-id>0074-3797_aa6f7aea-ddd9-b203-263b-0daad92b0ee4</ndc-id>
                <ndc-product-code>0074-3797</ndc-product-code>
                <dpd-id/>
                <started-marketing-on>2002-12-30</started-marketing-on>
                <ended-marketing-on/>
                <dosage-form>injection, solution</dosage-form>
                <strength>40 mg/.8mL</strength>
                <route>subcutaneous</route>
                <fda-application-number>BLA125057</fda-application-number>
                <generic>false</generic>
                <over-the-counter>false</over-the-counter>
                <approved>true</approved>
                <country>US</country>
                <source>FDA NDC</source>
            </product>
        </products>
        <international-brands>
            <international-brand>
                <name>Humira Pen</name>
                <company>Abbott Laboratories</company>
            </international-brand>
        </international-brands>
        <mixtures>
            <mixture>
                <name>Humira</name>
                <ingredients>Adalimumab</ingredients>
            </mixture>
            <mixture>
                <name>Humira</name>
                <ingredients>Adalimumab</ingredients>
            </mixture>
        </mixtures>
        <packagers>
            <packager>
                <name>Abbott Laboratories Ltd.</name>
                <url>http://www.abbott.com</url>
            </packager>
            <packager>
                <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
                <url>http://www.vetter-pharma.com</url>
            </packager>
        </packagers>
        <manufacturers/>
        <prices>
            <price>
                <description>Humira 20 mg/0.4 ml syringe</description>
                <cost currency="USD">959.19</cost>
                <unit>syringe</unit>
            </price>
            <price>
                <description>Humira 40 mg/0.8 ml pen</description>
                <cost currency="USD">959.19</cost>
                <unit>pen</unit>
            </price>
            <price>
                <description>Humira crohn's starter pack</description>
                <cost currency="USD">959.19</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Humira psoriasis starter pack</description>
                <cost currency="USD">959.19</cost>
                <unit>each</unit>
            </price>
            <price>
                <description>Humira (1 Box = Two 40 mg/0.8ml Syringes) Box</description>
                <cost currency="USD">1995.1</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Humira 2 20 mg/0.4ml Kit 1 Box = Two 20 mg/0.4ml Syringes</description>
                <cost currency="USD">1995.1</cost>
                <unit>box</unit>
            </price>
            <price>
                <description>Humira Pen 2 40 mg/0.8ml Kit (1 Box = 1 Kit Containing Two 40 mg/0.8ml Pens)</description>
                <cost currency="USD">1995.1</cost>
                <unit>box</unit>
            </price>
        </prices>
        <categories>
            <category>
                <category>Antirheumatic Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Anti-Inflammatory Agents</category>
                <mesh-id/>
            </category>
            <category>
                <category>Immunosuppressive Agents</category>
                <mesh-id/>
            </category>
        </categories>
        <affected-organisms>
            <affected-organism>Humans and other mammals</affected-organism>
        </affected-organisms>
        <dosages>
            <dosage>
                <form>Injection, solution</form>
                <route>subcutaneous</route>
                <strength>40 mg/.8mL</strength>
            </dosage>
            <dosage>
                <form>Solution</form>
                <route>subcutaneous</route>
                <strength>40 mg</strength>
            </dosage>
        </dosages>
        <atc-codes>
            <atc-code code="L04AB04">
                <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
                <level code="L04">IMMUNOSUPPRESSANTS</level>
                <level code="L04A">IMMUNOSUPPRESSANTS</level>
                <level code="L04AB">Tumor necrosis factor alpha (TNF-α) inhibitors</level>
            </atc-code>
        </atc-codes>
        <ahfs-codes>
            <ahfs-code>92:00.00</ahfs-code>
        </ahfs-codes>
        <patents>
            <patent>
                <number>2243459</number>
                <country>Canada</country>
                <approved>2002-09-17</approved>
                <expires>2017-02-10</expires>
            </patent>
        </patents>
        <food-interactions/>
        <drug-interactions>
            <drug-interaction>
                <drugbank-id>DB01281</drugbank-id>
                <name>Abatacept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01223</drugbank-id>
                <name>Aminophylline</name>
                <description>May decrease the serum concentration of Theophylline Derivatives.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00026</drugbank-id>
                <name>Anakinra</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08879</drugbank-id>
                <name>Belimumab</name>
                <description>Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06168</drugbank-id>
                <name>Canakinumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08904</drugbank-id>
                <name>Certolizumab pegol</name>
                <description>Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab pegol.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00091</drugbank-id>
                <name>Cyclosporine</name>
                <description>May decrease the serum concentration of Cyclosporine (Systemic).</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06643</drugbank-id>
                <name>Denosumab</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00065</drugbank-id>
                <name>Infliximab</name>
                <description>Adalimumab may enhance the immunosuppressive effect of Infliximab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01097</drugbank-id>
                <name>Leflunomide</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00108</drugbank-id>
                <name>Natalizumab</name>
                <description>Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00337</drugbank-id>
                <name>Pimecrolimus</name>
                <description>May enhance the adverse/toxic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06372</drugbank-id>
                <name>Rilonacept</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB01656</drugbank-id>
                <name>Roflumilast</name>
                <description>May enhance the immunosuppressive effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06688</drugbank-id>
                <name>Sipuleucel-T</name>
                <description>Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00277</drugbank-id>
                <name>Theophylline</name>
                <description>May decrease the serum concentration of Theophylline Derivatives.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB06273</drugbank-id>
                <name>Tocilizumab</name>
                <description>May enhance the immunosuppressive effect of Anti-TNF Agents.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB08895</drugbank-id>
                <name>Tofacitinib</name>
                <description>Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00072</drugbank-id>
                <name>Trastuzumab</name>
                <description>May enhance the neutropenic effect of Immunosuppressants.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB09033</drugbank-id>
                <name>Vedolizumab</name>
                <description>Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab.</description>
            </drug-interaction>
            <drug-interaction>
                <drugbank-id>DB00682</drugbank-id>
                <name>Warfarin</name>
                <description>Adalimumab may decrease the serum concentration of Warfarin.</description>
            </drug-interaction>
        </drug-interactions>
        <sequences>
            <sequence format="FASTA">&gt; Light chain:
                DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPS
                RFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPP
                SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
                LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</sequence>
            <sequence format="FASTA">&gt; Heavy chain:
                EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDY
                ADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVS
                SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
                SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</sequence>
        </sequences>
        <experimental-properties>
            <property>
                <kind>Hydrophobicity</kind>
                <value>-0.441</value>
                <source/>
            </property>
            <property>
                <kind>Isoelectric Point</kind>
                <value>8.25</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Weight</kind>
                <value>144190.3000</value>
                <source/>
            </property>
            <property>
                <kind>Molecular Formula</kind>
                <value>C6428H9912N1694O1987S46</value>
                <source/>
            </property>
        </experimental-properties>
        <external-identifiers>
            <external-identifier>
                <resource>Drugs Product Database (DPD)</resource>
                <identifier>13356</identifier>
            </external-identifier>
            <external-identifier>
                <resource>National Drug Code Directory</resource>
                <identifier>0074-3799-02</identifier>
            </external-identifier>
            <external-identifier>
                <resource>GenBank</resource>
                <identifier>J00228</identifier>
            </external-identifier>
            <external-identifier>
                <resource>PharmGKB</resource>
                <identifier>PA10004</identifier>
            </external-identifier>
            <external-identifier>
                <resource>UniProtKB</resource>
                <identifier>P01857</identifier>
            </external-identifier>
            <external-identifier>
                <resource>Wikipedia</resource>
                <identifier>Adalimumab</identifier>
            </external-identifier>
        </external-identifiers>
        <external-links>
            <external-link>
                <resource>RxList</resource>
                <url>http://www.rxlist.com/cgi/generic3/humira.htm</url>
            </external-link>
            <external-link>
                <resource>Drugs.com</resource>
                <url>http://www.drugs.com/cdi/adalimumab.html</url>
            </external-link>
        </external-links>
        <pathways/>
        <reactions/>
        <snp-effects/>
        <snp-adverse-drug-reactions/>
        <targets>
            <target>
                <id>BE0000704</id>
                <name>Tumor necrosis factor</name>
                <organism>Human</organism>
                <actions>
                    <action>antibody</action>
                </actions>
                <references># Lorenz HM: Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002 Apr;4(2):185-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12044041&#13;
                    # Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii30-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14532145&#13;
                    # Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M: [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies] Rev Med Chil. 2003 Dec;131(12):1445-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15022409&#13;
                    # Bang LM, Keating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs. 2004;18(2):121-39. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15046527&#13;
                    # Klinkhoff A: Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs. 2004;64(12):1267-83. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15200343&#13;
                    # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
                <known-action>yes</known-action>
                <polypeptide id="P01375" source="Swiss-Prot">
                    <name>Tumor necrosis factor</name>
                    <general-function>Involved in tumor necrosis factor receptor binding</general-function>
                    <specific-function>Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin 1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation</specific-function>
                    <gene-name>TNF</gene-name>
                    <locus>6p21.3</locus>
                    <cellular-location>Cell membrane; single-pass type II membrane protein. Processed form:Secreted protein. Also exists as</cellular-location>
                    <transmembrane-regions>36-56</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.92</theoretical-pi>
                    <molecular-weight>25645.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:11892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>TNF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>TNF</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M16441</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>339741</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P01375</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>TNFA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Cachectin</synonym>
                        <synonym>TNF-a</synonym>
                        <synonym>TNF-alpha</synonym>
                        <synonym>Tumor necrosis factor ligand superfamily member 2</synonym>
                        <synonym>Tumor necrosis factor precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Tumor necrosis factor precursor
                        MSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR
                        EEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR
                        DNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE
                        TPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG
                        ACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC
                        GTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG
                        GAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT
                        TCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG
                        CAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA
                        GATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC
                        AAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC
                        GTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG
                        ACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC
                        CAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT
                        GCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00229</identifier>
                            <name>TNF</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>membrane</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>signal transducer activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cytokine activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>tumor necrosis factor receptor binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000901</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="O75015" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-B</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils</specific-function>
                    <gene-name>FCGR3B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane; lipid-anchor; GPI-anchor. Secreted protein. Note=Secreted after cleavage</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.71</theoretical-pi>
                    <molecular-weight>26216.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3620</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X16863</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31322</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>O75015</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16b antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-beta</synonym>
                        <synonym>Fc-gamma RIIIb</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIb</synonym>
                        <synonym>IgG Fc receptor III-1</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-B precursor
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN
                        VSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;702 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA
                        AAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002093</id>
                <name>Complement C1r subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P00736" source="Swiss-Prot">
                    <name>Complement C1r subcomponent</name>
                    <general-function/>
                    <specific-function>C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system</specific-function>
                    <gene-name>C1R</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.24</theoretical-pi>
                    <molecular-weight>80174.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1246</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1R</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X04701</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>29539</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P00736</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1R_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1r subcomponent precursor</synonym>
                        <synonym>Complement component 1, r subcomponent</synonym>
                        <synonym>EC 3.4.21.41</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1r subcomponent
                        MWLLYLLVPALFCRAGGSIPIPQKLFGEVTSPLFPKPYPNNFETTTVITVPTGYRVKLVF
                        QQFDLEPSEGCFYDYVKISADKKSLGRFCGQLGSPLGNPPGKKEFMSQGNKMLLTFHTDF
                        SNEENGTIMFYKGFLAYYQAVDLDECASRSKSGEEDPQPQCQHLCHNYVGGYFCSCRPGY
                        ELQEDRHSCQAECSSELYTEASGYISSLEYPRSYPPDLRCNYSIRVERGLTLHLKFLEPF
                        DIDDHQQVHCPYDQLQIYANGKNIGEFCGKQRPPDLDTSSNAVDLLFFTDESGDSRGWKL
                        RYTTEIIKCPQPKTLDEFTIIQNLQPQYQFRDYFIATCKQGYQLIEGNQVLHSFTAVCQD
                        DGTWHRAMPRCKIKDCGQPRNLPNGDFRYTTTMGVNTYKARIQYYCHEPYYKMQTRAGSR
                        ESEQGVYTCTAQGIWKNEQKGEKIPRCLPVCGKPVNPVEQRQRIIGGQKAKMGNFPWQVF
                        TNIHGRGGGALLGDRWILTAAHTLYPKEHEAQSNASLDVFLGHTNVEELMKLGNHPIRRV
                        SVHPDYRQDESYNFEGDIALLELENSVTLGPNLLPICLPDNDTFYDLGLMGYVSGFGVME
                        EKIAHDLRFVRLPVANPQACENWLRGKNRMDVFSQNMFCAGHPSLKQDACQGDSGGVFAV
                        RDPNTDRWVATGIVSWGIGCSRGYGFYTKVLNYVDWIKKEMEEED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2118 bp
                        ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCC
                        ATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAAC
                        AACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTC
                        CAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCT
                        GATAAGAAAAGCCTGGGGAGGTTCTGTGGGCAACTGGGTTCTCCACTGGGCAACCCCCCG
                        GGAAAGAAGGAATTTATGTCCCAAGGGAACAAGATGCTGCTGACCTTCCACACAGACTTC
                        TCCAACGAGGAGAATGGGACCATCATGTTCTACAAGGGCTTCCTGGCCTACTACCAAGCT
                        GTGGACCTTGATGAATGTGCTTCCCGGAGCAAATTAGGGGAGGAGGATCCCCAGCCCCAG
                        TGCCAGCACCTGTGTCACAACTACGTTGGAGGCTACTTCTGTTCCTGCCGTCCAGGCTAT
                        GAGCTTCAGGAAGACAGGCATTCCTGCCAGGCTGAGTGCAGCAGCGAGCTGTACACGGAG
                        GCATCAGGCTACATCTCCAGCCTGGAGTACCCTCGGTCCTACCCCCCTGACCTGCGCTGC
                        AACTACAGCATCCGGGTGGAGCGGGGCCTCACCCTGCACCTCAAGTTCCTGGAGCCTTTT
                        GATATTGATGACCACCAGCAAGTACACTGCCCCTATGACCAGCTACAGATCTATGCCAAC
                        GGGAAGAACATTGGCGAGTTCTGTGGGAAGCAAAGGCCCCCCGACCTCGACACCAGCAGC
                        AATGCTGTGGATCTGCTGTTCTTCACAGATGAGTCGGGGGACAGCCGGGGCTGGAAGCTG
                        CGCTACACCACCGAGATCATCAAGTGCCCCCAGCCCAAGACCCTAGACGAGTTCACCATC
                        ATCCAGAACCTGCAGCCTCAGTACCAGTTCCGTGACTACTTCATTGCTACCTGCAAGCAA
                        GGCTACCAGCTCATAGAGGGGAACCAGGTGCTGCATTCCTTCACAGCTGTCTGCCAGGAT
                        GATGGCACGTGGCATCGTGCCATGCCCAGATGCAAGATCAAGGACTGTGGGCAGCCCCGA
                        AACCTGCCTAATGGTGACTTCCGTTACACCACCACAATGGGAGTGAACACCTACAAGGCC
                        CGTATCCAGTACTACTGCCATGAGCCATATTACAAGATGCAGACCAGAGCTGGCAGCAGG
                        GAGTCTGAGCAAGGGGTGTACACCTGCACAGCACAGGGCATTTGGAAGAATGAACAGAAG
                        GGAGAGAAGATTCCTCGGTGCTTGCCAGTGTGTGGGAAGCCCGTGAACCCCGTGGAACAG
                        AGGCAGCGCATCATCGGAGGGCAAAAAGCCAAGATGGGCAACTTCCCCTGGCAGGTGTTC
                        ACCAACATCCACGGGCGCGGGGGCGGGGCCCTGCTGGGCGACCGCTGGATCCTCACAGCT
                        GCCCACACCCTGTATCCCAAGGAACACGAAGCGCAAAGCAACGCCTCTTTGGATGTGTTC
                        CTGGGCCACACAAATGTGGAAGAGCTCATGAAGCTAGGAAATCACCCCATCCGCAGGGTC
                        AGCGTCCACCCGGACTACCGTCAGGATGAGTCCTACAATTTTGAGGGGGACATCGCCCTG
                        CTGGAGCTGGAAAATAGTGTCACCCTGGGTCCCAACCTCCTCCCCATCTGCCTCCCTGAC
                        AACGATACCTTCTACGACCTGGGCTTGATGGGCTATGTCAGTGGCTTCGGGGTCATGGAG
                        GAGAAGATTGCTCATGACCTCAGGTTTGTCCGTCTGCCCGTAGCTAATCCACAGGCCTGT
                        GAGAACTGGCTCCGGGGAAAGAATAGGATGGATGTGTTCTCTCAAAACATGTTCTGTGCT
                        GGACACCCATCTCTAAAGCAGGACGCCTGCCAGGGGGATAGTGGGGGCGTTTTTGCAGTA
                        AGGGACCCGAACACTGATCGCTGGGTGGCCACGGGCATCGTGTCCTGGGGCATCGGGTGC
                        AGCAGGGGCTATGGCTTCTACACCAAAGTGCTCAACTACGTGGACTGGATCAAGAAAGAG
                        ATGGAGGAGGAGGACTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF07645</identifier>
                            <name>EGF_CA</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002094</id>
                <name>Complement C1q subcomponent subunit A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02745" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit A</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QA</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>9.45</theoretical-pi>
                    <molecular-weight>26017.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1241</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QA</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF135157</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4894854</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02745</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QA_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit A
                        MEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR
                        TGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI
                        RRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR
                        GQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL
                        IFPSA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG
                        GTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC
                        AGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG
                        ACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC
                        AAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGGGCCCGTGGCATCCCGGGAATTAAA
                        GGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT
                        CGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG
                        GAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC
                        TTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG
                        GGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG
                        GTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC
                        CCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC
                        ATCTTCCCATCTGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002095</id>
                <name>Complement C1q subcomponent subunit B</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02746" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit B</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QB</gene-name>
                    <locus>1p36.12</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.87</theoretical-pi>
                    <molecular-weight>26460.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1242</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QB</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X03084</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>573114</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02746</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QB_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit B precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit B
                        MKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKGEK
                        GLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQKI
                        AFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNLCV
                        NLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANSIF
                        SGFLLFPDMEA</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;688 bp
                        CCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGG
                        GACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCC
                        AGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAA
                        TCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGCCCAGGGGCCCCTGG
                        AGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAGAAAATCGCCTTCTC
                        TGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATCCGCTTCGACCACGT
                        GATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTCACCTGCAAGGTGCC
                        CGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTGTGCGTGAACCTCAT
                        GCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTATGCCTACAACACCTT
                        CCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAGAACGTCTTCCTGCA
                        GGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGCATCTTTTCCGGGTT
                        CCTGCTCTTTCCAGATATGGAGGCCTGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002096</id>
                <name>Complement C1q subcomponent subunit C</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P02747" source="Swiss-Prot">
                    <name>Complement C1q subcomponent subunit C</name>
                    <general-function/>
                    <specific-function>C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes</specific-function>
                    <gene-name>C1QC</gene-name>
                    <locus>1p36.11</locus>
                    <cellular-location>Secreted protein</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.58</theoretical-pi>
                    <molecular-weight>25774.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1245</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1QC</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>AF087892</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>33150626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P02747</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1QC_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>Complement C1q subcomponent subunit C precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1q subcomponent subunit C
                        MDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP
                        GIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS
                        VFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV
                        LLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF
                        LLFPD</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;738 bp
                        ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG
                        CTGCTGCCCCTCAGGGCCAAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC
                        CTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA
                        GGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA
                        CCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC
                        CCCATGGGATTCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA
                        GTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC
                        AACGCGGTCCTCACCAACCCGCAGGAGGATTATGACACGAGCACTGGCAAGTTCACCTGC
                        AAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG
                        CTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT
                        CAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT
                        GTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC
                        CTGCTCTTCCCCGACTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF01391</identifier>
                            <name>Collagen</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00386</identifier>
                            <name>C1q</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>cell</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>intracellular</description>
                        </go-classifier>
                        <go-classifier>
                            <category>component</category>
                            <description>cytoplasm</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>ion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>inorganic anion transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>phosphate transport</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002097</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P08637" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor III-A</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis</specific-function>
                    <gene-name>FCGR3A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>209-229</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.21</theoretical-pi>
                    <molecular-weight>29089.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3619</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR3A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X52645</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31324</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P08637</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG3A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD16a antigen</synonym>
                        <synonym>Fc-gamma RIII</synonym>
                        <synonym>Fc-gamma RIII-alpha</synonym>
                        <synonym>Fc-gamma RIIIa</synonym>
                        <synonym>FcR-10</synonym>
                        <synonym>FcRIII</synonym>
                        <synonym>FcRIIIa</synonym>
                        <synonym>IgG Fc receptor III-2</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor III-A precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor III-A
                        MWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW
                        FHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE
                        EDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN
                        VSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW
                        KDHKFKWRKDPQDK</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;765 bp
                        ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT
                        GAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAG
                        GACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG
                        TTTCACAATGAGAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA
                        GTCGACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG
                        CAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG
                        GAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA
                        TATTTACAGAATGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCA
                        AAAGCCACACTCAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAAT
                        GTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA
                        TCATTCTTTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA
                        GTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGG
                        AAGGACCATAAATTTAAATGGAGAAAGGACCCTCAAGACAAATGA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0001529</id>
                <name>Complement C1s subcomponent</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P09871" source="Swiss-Prot">
                    <name>Complement C1s subcomponent</name>
                    <general-function>Involved in calcium ion binding</general-function>
                    <specific-function>C1s B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4</specific-function>
                    <gene-name>C1S</gene-name>
                    <locus>12p13</locus>
                    <cellular-location>Cytoplasmic</cellular-location>
                    <transmembrane-regions>None</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>4.59</theoretical-pi>
                    <molecular-weight>76685.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:1247</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>C1S</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X06596</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>763110</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P09871</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>C1S_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>C1 esterase</synonym>
                        <synonym>Complement C1s subcomponent precursor</synonym>
                        <synonym>EC 3.4.21.42</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Complement C1s subcomponent precursor
                        MWCIVLFSLLAWVYAEPTMYGEILSPNYPQAYPSEVEKSWDIEVPEGYGIHLYFTHLDIE
                        LSENCAYDSVQIISGDTEEGRLCGQRSSNNPHSPIVEEFQVPYNKLQVIFKSDFSNEERF
                        TGFAAYYVATDINECTDFVDVPCSHFCNNFIGGYFCSCPPEYFLHDDMKNCGVNCSGDVF
                        TALIGEIASPNYPKPYPENSRCEYQIRLEKGFQVVVTLRREDFDVEAADSAGNCLDSLVF
                        VAGDRQFGPYCGHGFPGPLNIETKSNALDIIFQTDLTGQKKGWKLRYHGDPMPCPKEDTP
                        NSVWEPAKAKYVFRDVVQITCLDGFEVVEGRVGATSFYSTCQSNGKWSNSKLKCQPVDCG
                        IPESIENGKVEDPESTLFGSVIRYTCEEPYYYMENGGGGEYHCAGNGSWVNEVLGPELPK
                        CVPVCGVPREPFEEKQRIIGGSDADIKNFPWQVFFDNPWAGGALINEYWVLTAAHVVEGN
                        REPTMYVGSTSVQTSRLAKSKMLTPEHVFIHPGWKLLEVPEGRTNFDNDIALVRLKDPVK
                        MGPTVSPICLPGTSSDYNLMDGDLGLISGWGRTEKRDRAVRLKAARLPVAPLRKCKEVKV
                        EKPTADAEAYVFTPNMICAGGEKGMDSCKGDSGGAFAVQDPNDKTKFYAAGLVSWGPQCG
                        TYGLYTRVKNYVDWIMKTMQENSTPRED</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;2067 bp
                        ATGTGGTGCATTGTCCTGTTTTCACTTTTGGCATGGGTTTATGCTGAGCCTACCATGTAT
                        GGGGAGATCCTGTCCCCTAACTATCCTCAGGCATATCCCAGTGAGGTAGAGAAATCTTGG
                        GACATAGAAGTTCCTGAAGGGTATGGGATTCACCTCTACTTCACCCATCTGGACATTGAG
                        CTGTCAGAGAACTGTGCGTATGACTCAGTGCAGATAATCTCAGGAGACACTGAAGAAGGG
                        AGGCTCTGTGGACAGAGGAGCAGTAACAATCCCCACTCTCCAATTGTGGAAGAGTTCCAA
                        GTCCCATACAACAAACTCCAGGTGATCTTTAAGTCAGACTTTTCCAATGAAGAGCGTTTT
                        ACGGGGTTTGCTGCATACTATGTTGCCACAGACATAAATGAATGCACAGATTTTGTAGAT
                        GTCCCTTGTAGCCACTTCTGCAACAATTTCATTGGTGGTTACTTCTGCTCCTGCCCCCCG
                        GAATATTTCCTCCATGATGACATGAAGAATTGCGGAGTTAATTGCAGTGGGGATGTATTC
                        ACTGCACTGATTGGGGAGATTGCAAGTCCCAATTATCCCAAACCATATCCAGAGAACTCA
                        AGGTGTGAATACCAGATCCGGTTGGAGAAAGGGTTCCAAGTGGTGGTGACCTTGCGGAGA
                        GAAGATTTTGATGTGGAAGCAGCTGACTCAGCGGGAAACTGCCTTGACAGTTTAGTTTTT
                        GTTGCAGGAGATCGGCAATTTGGTCCTTACTGTGGTCATGGATTCCCTGGGCCTCTAAAT
                        ATTGAAACCAAGAGTAATGCTCTTGATATCATCTTCCAAACTGATCTAACAGGGCAAAAA
                        AAGGGCTGGAAACTTCGCTATCATGGAGATCCAATGCCCTGCCCTAAGGAAGACACTCCC
                        AATTCTGTTTGGGAGCCTGCGAAGGCAAAATATGTCTTTAGAGATGTGGTGCAGATAACC
                        TGTCTGGATGGGTTTGAAGTTGTGGAGGGACGTGTTGGTGCAACATCTTTCTATTCGACT
                        TGTCAAAGCAATGGAAAGTGGAGTAATTCCAAACTGAAATGTCAACCTGTGGACTGTGGC
                        ATTCCTGAATCCATTGAGAATGGTAAAGTTGAAGACCCAGAGAGCACTTTGTTTGGTTCT
                        GTCATCCGCTACACTTGTGAGGAGCCATATTACTACATGGAAAATGGAGGAGGTGGGGAG
                        TATCACTGTGCTGGTAACGGGAGCTGGGTGAATGAGGTGCTGGGCCCGGAGCTGCCGAAA
                        TGTGTTCCAGTCTGTGGAGTCCCCAGAGAACCCTTTGAAGAAAAACAGAGGATAATTGGA
                        GGATCCGATGCAGATATTAAAAACTTCCCCTGGCAAGTCTTCTTTGACAACCCATGGGCT
                        GGTGGAGCGCTCATTAATGAGTACTGGGTGCTGACGGCTGCTCATGTTGTGGAGGGAAAC
                        AGGGAGCCAACAATGTATGTTGGGTCCACCTCAGTGCAGACCTCACGGCTGGCAAAATCC
                        AAGATGCTCACTCCTGAGCATGTGTTTATTCATCCGGGATGGAAGCTGCTGGAAGTCCCA
                        GAAGGACGAACCAATTTTGATAATGACATTGCACTGGTGCGGCTGAAAGACCCAGTGAAA
                        ATGGGACCCACCGTCTCTCCCATCTGCCTACCAGGCACCTCTTCCGACTACAACCTCATG
                        GATGGGGACCTGGGACTGATCTCAGGCTGGGGCCGAACAGAGAAGAGAGATCGTGCTGTT
                        CGCCTCAAGGCGGCAAGGTTACCTGTAGCTCCTTTAAGAAAATGCAAAGAAGTGAAAGTG
                        GAGAAACCCACAGCAGATGCAGAGGCCTATGTTTTCACTCCTAACATGATCTGTGCTGGA
                        GGAGAGAAGGGCATGGATAGCTGTAAAGGGGACAGTGGTGGGGCCTTTGCTGTACAGGAT
                        CCCAATGACAAGACCAAATTCTACGCAGCTGGCCTGGTGTCCTGGGGGCCCCAGTGTGGG
                        ACCTATGGGCTCTACACACGGGTAAAGAACTATGTTGACTGGATAATGAAGACTATGCAG
                        GAAAATAGCACCCCCCGTGAGGACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00008</identifier>
                            <name>EGF</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00089</identifier>
                            <name>Trypsin</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00084</identifier>
                            <name>Sushi</name>
                        </pfam>
                        <pfam>
                            <identifier>PF00431</identifier>
                            <name>CUB</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                        <go-classifier>
                            <category>component</category>
                            <description>extracellular region</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>catalytic activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>serine-type endopeptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>hydrolase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>cation binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>calcium ion binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>binding</description>
                        </go-classifier>
                        <go-classifier>
                            <category>function</category>
                            <description>peptidase activity</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>proteolysis</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>macromolecule metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>response to biotic stimulus</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>defense response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>cellular protein metabolism</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>humoral immune response</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>complement activation</description>
                        </go-classifier>
                        <go-classifier>
                            <category>process</category>
                            <description>physiological process</description>
                        </go-classifier>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0000710</id>
                <name>High affinity immunoglobulin gamma Fc receptor I</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12314" source="Swiss-Prot">
                    <name>High affinity immunoglobulin gamma Fc receptor I</name>
                    <general-function>Involved in receptor signaling protein activity</general-function>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. High affinity receptor</specific-function>
                    <gene-name>FCGR1A</gene-name>
                    <locus>1q21.2-q21.3</locus>
                    <cellular-location>Membrane; single-pass type I membrane protein</cellular-location>
                    <transmembrane-regions>293-313</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>8.08</theoretical-pi>
                    <molecular-weight>42632.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3613</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR1A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X14356</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>31332</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12314</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCGR1_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD64 antigen</synonym>
                        <synonym>Fc-gamma RI</synonym>
                        <synonym>FcRI</synonym>
                        <synonym>High affinity immunoglobulin gamma Fc receptor I precursor</synonym>
                        <synonym>IgG Fc receptor I</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;High affinity immunoglobulin gamma Fc receptor I precursor
                        MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG
                        TATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL
                        ALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG
                        ISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN
                        TSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG
                        IMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ
                        LQEGVHRKEPQGAT</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;1125 bp
                        ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA
                        AAGGCAGTGATCTCTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC
                        TTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC
                        ACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT
                        GGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC
                        CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG
                        GCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT
                        GGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA
                        AGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA
                        ATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC
                        CCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG
                        CCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC
                        ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC
                        GAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG
                        CTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA
                        ATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG
                        AAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAACTTCCAGC
                        CTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG
                        CTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002098</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P12318" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-a</name>
                    <general-function/>
                    <specific-function>Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens</specific-function>
                    <gene-name>FCGR2A</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.78</theoretical-pi>
                    <molecular-weight>34990.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3616</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2A</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>M31932</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>182474</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P12318</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2A_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-a</synonym>
                        <synonym>Fc-gamma-RIIa</synonym>
                        <synonym>FcRII-a</synonym>
                        <synonym>IgG Fc receptor II-a</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-a precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-a
                        MAMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL
                        TCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL
                        SEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSRLDPTFSIPQANHS
                        HSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY
                        CRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD
                        KNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;954 bp
                        ATGGCTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA
                        CCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG
                        GCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG
                        ACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT
                        CTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG
                        GAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT
                        TCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG
                        CTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA
                        AAATCCCAGAAATTCTCCCGTTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT
                        CACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT
                        GTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG
                        GCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC
                        TGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG
                        CCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC
                        TATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT
                        AAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002099</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31994" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-b</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B- cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis</specific-function>
                    <gene-name>FCGR2B</gene-name>
                    <locus>1q23</locus>
                    <cellular-location>Membrane</cellular-location>
                    <transmembrane-regions>218-240</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.12</theoretical-pi>
                    <molecular-weight>34044.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:3618</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2B</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>U87560</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>4099445</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31994</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2B_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-b</synonym>
                        <synonym>Fc-gamma-RIIb</synonym>
                        <synonym>FcRII-b</synonym>
                        <synonym>IgG Fc receptor II-b</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-b precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-b
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA
                        LEEPDDQNRI</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;930 bp
                        ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCTCTCCCAGGATACCCTGAG
                        TGCAGGGAAATGGGAGAGACCCTCCCTGAGAAACCAGCCAATCCCACTAATCCTGATGAG
                        GCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT
                        CTGGAAGAGCCTGATGACCAGAACCGTATT</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
            <target>
                <id>BE0002100</id>
                <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                <organism>Human</organism>
                <actions/>
                <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#13;
                    # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
                <known-action>unknown</known-action>
                <polypeptide id="P31995" source="Swiss-Prot">
                    <name>Low affinity immunoglobulin gamma Fc region receptor II-c</name>
                    <general-function/>
                    <specific-function>Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells</specific-function>
                    <gene-name>FCGR2C</gene-name>
                    <locus>1q23.3</locus>
                    <cellular-location>Cell membrane</cellular-location>
                    <transmembrane-regions>224-246</transmembrane-regions>
                    <signal-regions/>
                    <theoretical-pi>6.9</theoretical-pi>
                    <molecular-weight>35578.0</molecular-weight>
                    <chromosome-location/>
                    <organism ncbi-taxonomy-id="9606">Human</organism>
                    <external-identifiers>
                        <external-identifier>
                            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
                            <identifier>HGNC:15626</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenAtlas</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GeneCards</resource>
                            <identifier>FCGR2C</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Gene Database</resource>
                            <identifier>X17652</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>GenBank Protein Database</resource>
                            <identifier>32074</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProtKB</resource>
                            <identifier>P31995</identifier>
                        </external-identifier>
                        <external-identifier>
                            <resource>UniProt Accession</resource>
                            <identifier>FCG2C_HUMAN</identifier>
                        </external-identifier>
                    </external-identifiers>
                    <synonyms>
                        <synonym>CD32 antigen</synonym>
                        <synonym>CDw32</synonym>
                        <synonym>Fc-gamma RII-c</synonym>
                        <synonym>Fc-gamma-RIIc</synonym>
                        <synonym>FcRII-c</synonym>
                        <synonym>IgG Fc receptor II-c</synonym>
                        <synonym>Low affinity immunoglobulin gamma Fc region receptor II-c precursor</synonym>
                    </synonyms>
                    <amino-acid-sequence format="FASTA">&gt;Low affinity immunoglobulin gamma Fc region receptor II-c
                        MGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN
                        VLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL
                        SDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN
                        FSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA
                        VVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR
                        APTDDDKNIYLTLPPNDHVNSNN</amino-acid-sequence>
                    <gene-sequence format="FASTA">&gt;972 bp
                        ATGGGAATCCTGTCATTTTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG
                        TCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT
                        GCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC
                        GTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC
                        TCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG
                        TTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC
                        AGCGACCCTGTGCATCTGACAGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG
                        GAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG
                        GTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC
                        TTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCATTGCACAGGAAACATA
                        GGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA
                        CCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCTGCCATTGTTGCTGCT
                        GTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG
                        AAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT
                        GAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG
                        GCACCTACTGACGATGATAAAAACATCTACTTGACTCTTCCTCCCAACGACCATGTCAAC
                        AGTAATAACTAA</gene-sequence>
                    <pfams>
                        <pfam>
                            <identifier>PF00047</identifier>
                            <name>ig</name>
                        </pfam>
                    </pfams>
                    <go-classifiers>
                    </go-classifiers>
                </polypeptide>
            </target>
        </targets>
        <enzymes/>
        <carriers/>
        <transporters/>
    </drug>
</drugbank>
